D . Dheepa Manoha an. (2025). F om Bioma ke s o Risk Sco es: Ma e nal Fi s T imes e Dual Ma ke
Sc eening, Risk S a i ica ion o T isomy 21/18/13. MAR Oncology and Hema ology. (2025) 5:09
“F om Bioma ke s o Risk Sco es: Ma e nal Fi s T imes e Dual Ma ke
Sc eening, Risk S a i ica ion o T isomy 21/18/13”.
D . Dheepa Manoha an *
*Co espondence o: D . Dheepa Manoha an, MBBS MD Medical Di ec o , Specialis Mic obiologis ,
QLABS Clinical Labo a o y, Dubai.
Copy igh .
© 2025 D . Dheepa Manoha an This is an open access a icle dis ibu ed unde he C ea i e Commons
A ibu ion License, which pe mi s un es ic ed use, dis ibu ion, and ep oduc ion in any medium, p o ided
he o iginal wo k is p ope ly ci ed.
Recei ed: 09 Sep 2025
Published: 17 Sep 2025
MAR Oncology and Hema ology (2025) 5:09
Resea ch A icle
D . Dheepa Manoha an, MAR Oncology and Hema ology (2025) 5:09.
Page 2 o 09
D . Dheepa Manoha an. (2025). F om Bioma ke s o Risk Sco es: Ma e nal Fi s T imes e Dual Ma ke
Sc eening, Risk S a i ica ion o T isomy 21/18/13. MAR Oncology and Hema ology. (2025) 5:09
Backg ound
P ena al sc eening plays a i al ole in iden i ying p egnancies a inc eased isk o ch omosomal condi ions
such as Down’s synd ome (T isomy 21), Edwa ds synd ome (T isomy 18), and Pa au synd ome (T isomy 13).
Fi s imes e sc eening combines ma e nal se um bioma ke s— ee β-Human Cho ionic Gonado opin (β-
HCG) and P egnancy Associa ed Plasma P o ein A (PAPP-A)—wi h ul asound pa ame e s like Nuchal
T anslucency (NT) and C own Rump Leng h (CRL). These inpu s, when analyzed using alida ed so wa e
such as SSDW, allow o ea ly, non-in asi e isk s a i ica ion. By in eg a ing biochemical and sonog aphic
da a, his app oach suppo s imely clinical decisions and minimizes he need o in asi e diagnos ic
p ocedu es.
S udy Place: QLabs Clinical Labo a o y, Dubai
S udy Pe iod: Ma ch–Sep embe 2025
Me hods
This e ospec i e s udy was conduc ed a QLabs o e a 6-mon h pe iod (Ma ch–Sep embe 2025),
in ol ing 189 p egnan women sc eened exclusi ely in he i s imes e using SSDW so wa e.
Figu e 1
D . Dheepa Manoha an, MAR Oncology and Hema ology (2025) 5:09.
Page 3 o 09
D . Dheepa Manoha an. (2025). F om Bioma ke s o Risk Sco es: Ma e nal Fi s T imes e Dual Ma ke
Sc eening, Risk S a i ica ion o T isomy 21/18/13. MAR Oncology and Hema ology. (2025) 5:09
Coho O e iew
To al Pa ien s Sc eened: 189
S udy Du a ion: 6-mon h e ospec i e analysis
Mean Age: 30.99 yea s (Rep oduc i e age g oup)
Mean Weigh : 61.9 kg (Used o MoM no maliza ion)
Ges a ional Age a Sc eening: Median 88 days
T imes e Dis ibu ion: 100% Fi s T imes e
Non-Caucasian pa ien s: 1.6% (e hnic adjus men applied)
No his o y o ch omosomal anomalies, smoking, o diabe es
Biochemical ma ke s we e exp essed in Mul iples o Median (MoM) and in e p e ed using SSDW
algo i hms. NT measu emen s we e included in isk calcula ion. The SSDW cu -o o high isk was
se a 1:250 o T isomy 21, 18, and 13.
D . Dheepa Manoha an, MAR Oncology and Hema ology (2025) 5:09.
Page 4 o 09
D . Dheepa Manoha an. (2025). F om Bioma ke s o Risk Sco es: Ma e nal Fi s T imes e Dual Ma ke
Sc eening, Risk S a i ica ion o T isomy 21/18/13. MAR Oncology and Hema ology. (2025) 5:09
Figu e 2
D . Dheepa Manoha an, MAR Oncology and Hema ology (2025) 5:09.
Page 5 o 09
D . Dheepa Manoha an. (2025). F om Bioma ke s o Risk Sco es: Ma e nal Fi s T imes e Dual Ma ke
Sc eening, Risk S a i ica ion o T isomy 21/18/13. MAR Oncology and Hema ology. (2025) 5:09
Clinical Backg ound
P e ious Anomalies: None (No p io ch omosomal abno mali ies)
Smoke s / Diabe ics: None (No con ounding isk ac o s)
Non-Caucasian Pa ien s: 1.6% (E hnic adjus men applied in SSDW)
Figu e 3
D . Dheepa Manoha an, MAR Oncology and Hema ology (2025) 5:09.
Page 6 o 09
D . Dheepa Manoha an. (2025). F om Bioma ke s o Risk Sco es: Ma e nal Fi s T imes e Dual Ma ke
Sc eening, Risk S a i ica ion o T isomy 21/18/13. MAR Oncology and Hema ology. (2025) 5:09
Figu e 4
Figu e 5
D . Dheepa Manoha an, MAR Oncology and Hema ology (2025) 5:09.
Page 7 o 09
D . Dheepa Manoha an. (2025). F om Bioma ke s o Risk Sco es: Ma e nal Fi s T imes e Dual Ma ke
Sc eening, Risk S a i ica ion o T isomy 21/18/13. MAR Oncology and Hema ology. (2025) 5:09
Figu e 6
Figu e 7
D . Dheepa Manoha an, MAR Oncology and Hema ology (2025) 5:09.
Page 8 o 09
D . Dheepa Manoha an. (2025). F om Bioma ke s o Risk Sco es: Ma e nal Fi s T imes e Dual Ma ke
Sc eening, Risk S a i ica ion o T isomy 21/18/13. MAR Oncology and Hema ology. (2025) 5:09
Conclusion
Ou o 189 pa ien s sc eened, 3.72% we e lagged as high- isk o T isomy 21 based on SSDW analysis.
Ele a ed β-HCG and educed PAPP-A le els we e consis en wi h known biochemical ends in a ec ed
p egnancies. NT measu emen s showed bo de line ele a ion in lagged cases.
This s udy ein o ces he alue o i s imes e double ma ke sc eening combined wi h ul asound and
SSDW analy ics in iden i ying high- isk p egnancies ea ly—suppo ing imely clinical decisions and educing
eliance on in asi e es ing.
Figu e 8
Acknowledgmen s
G a i ude o ou echnical and en i e QLABS CLINICAL LABORATORY eam o hei dedica ion and
p ecision. This wo k e lec s ou sha ed commi men o excellence, inno a ion, and pa ien -cen e ed ca e, and
con inuous imp o emen . Special app ecia ion o ROCHE DIGNOSTICS and da a handling eam o SSDW
so wa e.
“Empowe ing ea ly de ec ion h ough da a-d i en sc eening”.
Disclaime s
This pos e p esen s e ospec i e sc eening da a analyzed using SSDW so wa e and is in ended o
educa ional and audi pu poses.
Risk es ima es a e p obabilis ic and should be in e p e ed in conjunc ion wi h clinical indings,
ul asound pa ame e s, and pa ien his o y.
Biochemical alues a e exp essed in Mul iples o Median (MoM), no malized o ma e nal weigh ,
ges a ional age, and e hnici y.
Sc eening ou comes do no con i m diagnosis and should be ollowed by app op ia e clinical
e alua ion and, whe e indica ed, con i ma o y es ing.
D . Dheepa Manoha an, MAR Oncology and Hema ology (2025) 5:09.
Page 9 o 09
D . Dheepa Manoha an. (2025). F om Bioma ke s o Risk Sco es: Ma e nal Fi s T imes e Dual Ma ke
Sc eening, Risk S a i ica ion o T isomy 21/18/13. MAR Oncology and Hema ology. (2025) 5:09
E hics S a emen
This e ospec i e analysis was conduc ed using anonymized pa ien da a in acco dance wi h ins i u ional
p o ocols. No pa ien -iden i iable in o ma ion was used, and all p ocedu es adhe ed o local egula ion
s anda ds o e hical da a epo ing and labo a o y p ac ice.
Re e ences
1. Nicolaides KH. Sc eening o e al ch omosomal abno mali ies. Bes P ac Res Clin Obs e Gynaecol.
2012;26(1):3–13.
2. Spence K e al. Fi s imes e sc eening o isomy 21: a e iew o biochemical and ul asound ma ke s.
P ena Diagn. 2000;20(6):523–529.
3. SSDW So wa e Use Manual, Ve sions 5 & 6 – Risk Calcula ion Algo i hms and MoM No maliza ion
P o ocols.
Med onic
